Nasdaq · Healthcare
VERACYTE, INC. (VCYT)
As-reported financials and recent SEC filings for VERACYTE, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$517.1M
Net income
$66.4M
Net margin
12.8%
Diluted EPS
$0.82
ROE
5.1%
P/E (TTM)
56.0×
Market cap
$4.83B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $517.1M | $445.8M | $361.1M | $296.5M | $219.5M |
| Gross profit | — | — | — | — | — |
| Operating income | $57.8M | $16.1M | $-85.8M | $-41.1M | $-81.9M |
| Net income | $66.4M | $24.1M | $-74.4M | $-36.6M | $-75.6M |
| Diluted EPS | $0.82 | $0.31 | $-1.02 | $-0.51 | $-1.11 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-22
View on EDGAR →1442026-06-18
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →Go deeper on VCYT
Search VERACYTE, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.